icon
0%

Cencora COR - News Analyzed: 3,844 - Last Week: 100 - Last Month: 500

⇑ Cencora COR: A Biotech Giant's Continued Momentum in Market

Cencora COR: A Biotech Giant's Continued Momentum in Market
The recent update on Cencora (COR) highlights its continuous robust performance and strategic acquisitions, notably scoring the massive $4.6 billion acquisition of Retina Consultants of America which is expected to boost growth. Cencora’s shares have been steadily acquired by various financial institutions such as B. Metzler seel. Sohn & Co. Holding AG and Eagle Asset Management Inc., with multiple analysts referring to it as a strong growth stock. Insider selling, particularly where Steven Collis is concerned, drew attention. Pacer Advisors reported high stake in Cencora while the stock's position increased for BNP PARIBAS ASSET MANAGEMENT Holding S.A Moreover, Cencora is expanding its leadership team. The company's shares have hit a fresh high, and analysts expect continued momentum and value appreciation. Cencora's dividends will also be increased to $0.55 per share. Finally, Cencora reported strong Q4 revenue growth while EPS estimates for FY25 have been established.

Cencora COR News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 23 Nov 2024 13:18:57 GMT - Rating 8 - Innovation 6 - Rumor 2

The email address you have entered is invalid.